Aminofen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aminofen

What is Aminofen? A Concise Overview

Property Description
Active Ingredient Acetaminophen (Paracetamol)
Pharmacological Class Analgesic and Antipyretic
Origin Synthetic Compound
Primary Forms Tablet, Capsule, Oral Solution, Intravenous Solution
Common Use Relief of Pain and Fever

Core Identity and Pharmacological Class

Aminofen is the name for a medicinal product containing the active chemical substance Acetaminophen, formally known by its international nonproprietary name (INN), Paracetamol. This drug is primarily classified as an Analgesic (pain reliever) and an Antipyretic (fever reducer), belonging to the class of Non-Opioid Analgesics.

Acetaminophen is used to treat mild to moderate pain and reduce fever by acting on the central nervous system. This action is clinically recognized for its efficacy in central pain management. This mechanism distinguishes it from Nonsteroidal Anti-inflammatory Drugs (NSAIDs) due to its minimal anti-inflammatory activity at standard doses. The compound itself is a synthetic compound, produced reliably through chemical synthesis.


Composition and Available Forms

The composition of Aminofen typically involves the Acetaminophen active ingredient alongside pharmaceutical excipients or an aqueous base. While often a single-ingredient product, it is also frequently found in combination formulas.

Its versatility is reflected in its multiple dosage form(s). Aminofen is most commonly administered orally as a Tablet or Capsule, but is also available as an Oral solution or Suspension—often formulated with concentrations optimized for pediatric use—and a sterile Intravenous solution for controlled administration in clinical settings. The parenteral form is available for situations when other routes of administration are inappropriate. This range of forms ensures the medicine can be safely administered across diverse patient needs, and its typical OTC status highlights its accessibility for general symptomatic management.

What side effects are possible with Aminofen?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse effects of Aminofen (Acetaminophen/Paracetamol) by frequency and the body system affected. These classifications structure the understanding of the medicine’s safety profile, focusing on officially documented risks.

Adverse Reaction Classification

Adverse reactions are formally grouped by System-Organ Class (SOC). Significant categories include Hepatobiliary Disorders, Skin and Subcutaneous Tissue Disorders, Immune System Disorders, and Blood and Lymphatic System Disorders. Effects such as nausea, vomiting, and headache are generally categorized as Common based on clinical data from certain formulations, while thrombocytopenia and agranulocytosis are considered Very Rare [EMA SmPC].

Serious Adverse Reactions

The most serious documented safety concerns include the risk of severe hepatic injury, which can progress to acute liver failure, and rare severe cutaneous adverse reactions (SCARs). The SCARs explicitly listed in regulatory communications include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP) [FDA Drug Safety Communication].

Regulatory Safety Constraints

The official label mandates specific constraints related to usage and pre-existing conditions. A key restriction is the explicit warning against using Aminofen alongside any other product containing acetaminophen to mitigate the risk of accidental overdose and subsequent hepatic injury. The medicine is contraindicated in individuals with severe hepatic impairment or active liver disease. Caution is also noted for those with severe renal impairment and patients with risk factors for glutathione deficiency, such as chronic alcoholism [FDA Label]. Prolonged, regular daily use of the substance should be avoided, and may be associated with the development of analgesic-overuse headache [EMA SmPC]. The safety profile is defined by these documented, label-based restrictions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official Overdose Manifestations

Overdose of Aminofen (Acetaminophen) may initially present with non-specific, mild symptoms such as nausea, vomiting, anorexia, diaphoresis (sweating), pallor, and general malaise. These early signs may resolve temporarily, which does not indicate resolution of toxicity.

The primary and life-threatening outcome documented is dose-dependent hepatic necrosis, leading to severe hepatic failure, potentially causing encephalopathy, coma, and death. Renal tubular necrosis and myocardial injury are also documented complications. Patients with pre-existing hepatic impairment or chronic alcoholism face a heightened risk of severe toxicity.

Mandatory Emergency Actions

The official regulatory guidance requires seeking immediate medical attention for any suspected overdose, even if no symptoms are present. Contacting a Poison Control Center immediately is also mandated by official guidance. Prompt medical management is essential due to the progressive nature of the toxicity.

Clinical Management and Monitoring

Management is guided by specific regulatory protocols, including immediate monitoring. Required procedures involve obtaining serial serum acetaminophen concentrations and assessing liver function through hepatic enzyme levels and coagulation parameters. The specific antidote, Acetylcysteine (NAC), must be administered promptly to mitigate severe injury. Supportive treatment, including activated charcoal if ingestion was recent, is also described in regulatory labels.

Therapeutic Uses of Aminofen

Aminofen is commonly used to provide symptomatic relief, offering supportive care in acute situations marked by symptoms related to physical discomfort. It is applied across therapeutic domains where short-term symptomatic assistance is needed, assisting patients to cope more steadily with difficult episodes. The medication is commonly used to help with mild to moderate pain and to reduce fever.

The medication helps address symptoms that interfere with daily comfort, such as various forms of headache, dental pain, musculoskeletal aches, and discomfort associated with menstrual periods or immunization. It is applied in conditions characterized by periods of heightened symptoms, including those related to cold and flu-like illnesses.

“It provides supportive relief that helps ease the overall symptom burden during episodes of heightened discomfort.”

Quick Fact: Relief for Pain and Fever

Aminofen is primarily utilized when pain or fever symptoms are classified as mild to moderate, generally providing a relevant level of support during phases when symptoms become more noticeable. It is applicable in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Population Eligibility Rules for Aminofen

The eligibility for using Aminofen (Acetaminophen/Paracetamol) is defined by regulatory authorities based on specific patient populations and pre-existing health conditions.

Absolute Contraindications

Official labeling states that Aminofen must not be used in patients with a known hypersensitivity to the active substance or in individuals diagnosed with severe hepatic impairment or severe active liver disease.

Approved and Restricted Populations

Population Group Regulatory Status
Adults and Adolescents Generally Approved Population.
Children/Infants Approved, subject to appropriate age/weight formulation.
Severe Renal Impairment Conditional Use; requires caution and monitoring.
Chronic Alcoholism Conditional Use; restricted due to increased toxicity risk.

The medicine is generally approved for use across adult and pediatric populations. However, specific intravenous formulations may be classified as use not established in infants younger than two years of age. Use in older adults is typically approved without specific restrictions solely based on advanced age.

Pregnancy and Lactation

Use during pregnancy is permitted conditionally; regulators advise using the lowest effective dose for the shortest duration necessary. The medicine is generally considered compatible with breastfeeding when used at standard therapeutic levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Aminofen (Acetaminophen/Paracetamol), often focusing on metabolic constraints and the potential for toxicity. The co-administration of Aminofen with any other product containing acetaminophen is formally restricted, as this combination significantly increases the documented risk of severe hepatic injury.

Interactions involving hepatic enzymes are noted with agents that induce or regulate the cytochrome enzyme CYP2E1, such as certain Antiepileptics (e.g., Carbamazepine, Phenytoin), which may increase the hepatotoxic potential by altering metabolism. The risk of severe liver damage is also formally documented as increased when Aminofen is combined with the habitual consumption of three or more alcoholic drinks per day.

Interaction Type Interacting Substance Official Regulatory Outcome
Exposure Alteration Probenecid, Metyrapone May increase Aminofen serum concentration by reducing clearance.
Pharmacodynamic Warfarin (Vitamin K antagonist) May result in enhanced anticoagulation and increased bleeding risk.
Administration Timing Cholestyramine Must be separated; recommended to administer at least one hour after Aminofen.

Furthermore, the medicine is formally contraindicated for use in patients with severe hepatic impairment or active liver disease. Caution is also advised for use in patients with severe renal impairment due to the potential for increased Aminofen exposure, as stated in prescribing information.

Mechanism of Action

Aminofen is a compound that operates through a dual mechanism involving the modulation of inflammatory and nociceptive signaling. Its primary action is the non-competitive, allosteric inhibition of the cyclooxygenase-2 (COX-2) enzyme. This selective inhibition reduces the enzymatic conversion of arachidonic acid, thereby decreasing the biosynthesis and release of inflammatory prostaglandins, primarily prostaglandin E2 (PGE2). This step is central to mitigating the perpetuation of the inflammatory cascade.

Simultaneously, Aminofen modulates the activity of the transient receptor potential vanilloid 1 (TRPV1) channel. This interaction alters the ion flux across the neural membrane, leading to a decrease in the excitability of sensory neurons, specifically within the dorsal horn. This dual modulation of both PGE2 production and neuronal sensitization pathways limits the inflammatory damage cascade and influences the signaling mechanisms involved in the resolution phase of inflammation.

Dosage and Administration Information

Aminofen (Acetaminophen/Paracetamol) is officially used through several approved routes for systemic administration. The approved dosage forms include oral options (tablets, capsules, solutions), rectal suppositories, and a sterile intravenous solution for controlled administration in clinical settings. The standard adult single dose typically ranges from 325 mg up to 1000 mg (one gram). Use is scheduled to maintain a minimum interval of four hours between administrations.

A fundamental principle is the strict adherence to the maximum total daily dose. This limit must not exceed 4000 mg (4 grams) over a 24-hour period, necessitating careful accounting of the active substance from all co-administered sources. Dosing requires high-level adjustments in specific populations: for patients weighing less than 50 kg, including children, the dose is determined by weight-based criteria, and the minimum dosing interval may be prolonged in cases of severe renal impairment.

Specific procedural requirements govern non-oral administration: the intravenous solution must be delivered as a slow infusion over a duration of at least 15 minutes. Use is typically intended to be short-term, limited to the duration of acute symptomatic episodes.

Recent Clinical Evidence

Research evidence / Overview of Studies for Aminofen

Evidence for Acute Pain and Fever Management

The majority of research on Aminofen was studied for use in short-term randomized controlled trials (RCTs) evaluating outcomes related to physical discomfort and systemic imbalance. These studies monitored physiological strain and patient-reported outcomes over defined time intervals. Research describes findings showing patterns related to measures of pain intensity and body temperature. Systematic reviews described patterns observed when symptom measures were compared to control interventions. The evidence for this core indication is derived primarily from high-quality study types, though follow-up durations were often limited to 4 to 24 hours.

Evidence in Special Populations and Clinical Contexts

Aminofen was studied for application in specific groups, including pediatric populations (children) to monitor outcomes related to systemic imbalance, such as fever. Studies were also conducted in critically ill adult patients and those managing post-surgical pain, where data show patterns related to patient-reported discomfort and consumption of other pain relief options. However, evidence quality varies across studies evaluated in older adults, and data for specific comorbid groups remain insufficient for long-term outcomes.

Long-Term Observational Research and Limitations

Research explored Aminofen in large-scale observational cohort studies monitoring long-term neurodevelopmental outcomes in offspring after maternal use was observed during pregnancy. Findings reported from this research scenario were mixed. Some studies reported patterns where data show statistical relationships to certain measurements, while others, including sibling-control analysis, described inconsistent or negligible patterns. This research does not determine a direct causal link.

A key research limitation across this domain is the risk of confounding by indication, which means the research cannot definitively separate the exposure from the effect of the underlying condition being treated. Comparative evidence is also lacking when examining different doses for outcomes related to systemic imbalance.

Key Studies & References

  1. Acetaminophen Drug Information (National Library of Medicine - MedlinePlus)
  2. Acetaminophen Prescribing Information (U.S. Food and Drug Administration - DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Aminofen (FAQ)

Q: How quickly should I expect Aminofen to start working?

Official information indicates that Aminofen is rapidly absorbed following oral administration. Peak levels in the bloodstream, reflecting the period when peak concentrations in the bloodstream are typically reached, are usually within 30 to 60 minutes.


Q: How long does the effect of one dose of Aminofen typically last?

Regulatory documents mandate a minimum time interval of four hours between administrations. This minimum interval is in place because the substance is typically eliminated from the body within a few hours, with an elimination half-life of approximately two to two-and-a-half hours.


Q: Is it true that Aminofen can affect the liver?

Official regulatory documents include specific warnings regarding the risk of liver damage. Taking more than the maximum recommended dose, or combining it with other products containing acetaminophen or with heavy alcohol consumption, significantly increases the risk of severe liver damage and acute liver failure.


Q: Is Aminofen approved for use in older adults?

Aminofen is generally approved for use in older adults without restrictions based only on advanced age. Regulatory information advises that, for all individuals, the substance should be used at the lowest effective dose for the shortest duration necessary to relieve symptoms.


Q: Has Aminofen been studied for use during pregnancy?

The use of Aminofen during pregnancy has been explored in large-scale observational studies. Official regulatory guidance permits its use conditionally, stating that the substance should be used at the lowest effective dose for the shortest duration necessary.


Q: For how long is Aminofen use generally intended?

Regulatory documents state that Aminofen use is typically intended to be short-term, primarily limited to the duration of acute symptoms. Prolonged, regular daily use of the substance should be avoided, as this may be associated with other health concerns.


Q: Why do people sometimes say Aminofen is less irritating to the stomach than NSAIDs?

Aminofen is classified differently from Nonsteroidal Anti-inflammatory Drugs (NSAIDs) because it shows minimal anti-inflammatory activity at standard doses. Its mechanism of action means it is not associated with the same risks of common gastrointestinal side effects, such as stomach irritation or bleeding, that are sometimes seen with traditional NSAIDs.


Q: Can taking too much Aminofen cause long-term problems?

Official warnings state that exceeding the maximum recommended daily limit significantly raises the risk of severe acute hepatic injury, which can lead to liver failure. Furthermore, chronic, heavy use has been associated with long-term problems affecting the liver and kidneys.


Q: Why must people with kidney problems be cautious with Aminofen?

Caution is specifically advised for people with severe kidney impairment. Because the kidneys are essential for clearing the drug from the body, impairment could reduce the clearance of the substance. This may increase drug exposure, potentially raising the risk of toxicity.


Q: Can Aminofen cause stomach upset?

Official safety information reports that common adverse effects of Aminofen include nausea and vomiting. Other types of general stomach upset or a loss of appetite are also reported in product information leaflets.


Q: What are the most common side effects people report with Aminofen?

Based on clinical data, common adverse effects of Aminofen include headache, nausea, and vomiting. Skin rash is also frequently reported in product information materials.


Q: Can children take Aminofen, and if so, at what age?

Aminofen is generally approved for use in both children and infants. However, eligibility is subject to the appropriate age and weight-based formulation, with doses calculated according to the child's weight.


Q: What should I do if I miss a scheduled dose of Aminofen?

Guidance on how to handle a missed dose is included in the specific Patient Information Leaflet (PIL) that comes with the medication. The guidance typically states that a double dose should not be taken to make up for a forgotten dose.


Q: Are there any specific foods or drinks to avoid while taking Aminofen?

The main restriction highlighted in regulatory documents concerns alcohol. There is a documented risk of severe liver damage when Aminofen is combined with the habitual consumption of three or more alcoholic drinks per day.


Q: Does Aminofen interact with common allergy medications?

Many over-the-counter allergy, cold, and flu medicines already contain the active ingredient acetaminophen. Regulatory information states that Aminofen should not be taken with any other product containing acetaminophen to prevent exceeding the safe daily limit.


Q: Do you need a prescription to buy Aminofen?

Aminofen (acetaminophen) is widely available over-the-counter (OTC) for common forms like tablets, capsules, and oral solutions. However, some specific high-strength or sterile intravenous forms of the medicine require a prescription.


Q: Are there generic versions of Aminofen available?

Yes, the active ingredient acetaminophen (paracetamol) is the generic name itself. Generic versions of the medication are widely available and are regulated to meet the same quality standards for strength and effectiveness as brand-name products.


Q: Can Aminofen cause a skin rash or allergic reaction?

Yes, a skin rash or allergic reaction is possible with Aminofen use. Regulatory communications highlight the risk of rare but serious cutaneous adverse reactions (SCARs) and hypersensitivity, which require immediate attention.


Q: How is Aminofen cleared from the body?

The official product information explains that Aminofen is primarily processed, or metabolized, by the liver. It is then removed from the body primarily through excretion by the kidneys.


Q: What kind of research supports the use of Aminofen for muscle pain?

Aminofen is supported by high-quality research, including short-term randomized controlled trials, for the management of 'acute pain.' Its use for muscle aches falls under its general, approved indication for the relief of mild to moderate pain.


Q: Is it okay to crush or split Aminofen tablets?

Whether standard tablets can be split depends on the formulation and whether the product label indicates the tablet is 'scored.' However, formulations that are modified-release or extended-release are typically not intended to be crushed, split, or chewed, as this may alter the intended release of the medication.


Q: Do alcohol and Aminofen mix?

The combination of Aminofen and alcohol is formally documented to increase the risk of severe liver damage. This risk is particularly noted for individuals who habitually consume three or more alcoholic drinks per day.


Q: Are there different strengths of Aminofen available?

Yes, different strengths are available on the market. Official information for adults describes a standard single dose range typically from 325 mg up to 1000 mg (one gram).


Q: Is Aminofen effective for nerve pain?

The primary official indications for Aminofen are for general pain and fever. Some scientific reviews note that the evidence is limited to support the use of Aminofen specifically for certain chronic conditions like neuropathic (nerve) pain.


Q: What kind of evidence exists for Aminofen's safety profile?

The safety profile is defined by officially documented risks, including severe hepatic injury and rare severe skin reactions. This information is derived from comprehensive data, including clinical trial results and ongoing post-marketing surveillance reports.


Q: Can Aminofen be used for dental pain relief?

Aminofen is officially indicated for the relief of mild to moderate pain. Regulatory information supports its use for acute pain, which includes conditions such as pain following a dental procedure, falling under its approved analgesic use.


Q: How do doctors monitor the effectiveness of Aminofen in patients?

In clinical practice, effectiveness is monitored by doctors primarily by assessing patient-reported outcomes related to pain intensity. They also monitor systemic measures like body temperature when treating fever.

How should Aminofen be stored and disposed of?

How to Store and Dispose of Aminofen?

Aminofen (Acetaminophen) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Regulatory guidelines mandate that the medication must be kept in its original container, tightly closed, and stored in a dry place to protect it from moisture. It is strictly required that the product be protected from freezing and avoid excessive heat above 40 C (104 F). All forms of Aminofen must be kept out of the sight and reach of children.

Official Disposal Instructions

The preferred method for discarding expired or unused Aminofen is through a government-authorized drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before disposal in the household trash. The medication must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aminofen found in:

A-Z Index: